Clinical Trial Update: Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the probiotic L. reuteri NCIMB 30242 and its impact on the plasma bile acid profile in adults with hypercholesterolemia has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• L. reuteri NCIMB 30242 (Lactobacillus reuteri NCIMB 30242)

Snippet

Sponsor: Micropharma Limited | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED